News Column

8 IPOs Planned for the Week of February 10

February 10, 2014

Francis Gaskins



The full IPO calendar is available at IPOpremium.com

Ranked by size of IPO, largest first.

(1) Based in Troy, MI, Talmer Bancorp (TLMR) scheduled a $210 million IPO on the Nasdaq with a market capitalization of $1 billion at a price range midpoint of $13.50 for Wednesday, February 12, 2014.

Between April 30, 2010 and December 31, 2013, TLMR successfully completed five community bank acquisitions totaling $5 billion in assets and $4.9 billion in liabilities.

(2) Based in Columbus, OH,Installed Building Products (IBP) scheduled a $135 million IPO on the NYSE with a market capitalization of $432 million at a price range midpoint of $15 for Thursday, February 13, 2014.

IBP is the second largest new residential insulation installer in the United States based on its internal estimates, with a national platform consisting of over 100 locations serving customers in 44 states.

(3) Based in Goleta, CA, Inogen (INGN) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $306 million at a price range midpoint of $17 for Friday, February 14, 2014.

INGN believes it is the only portable oxygen concentrator manufacturer that employs a direct-to-consumer marketing strategy in the United States

(4) Based in Lexington, MA, Concert Pharmaceuticals (CNCE) scheduled a $65 million IPO on the Nasdaq with a market capitalization of $211 million at a price range midpoint of $13 for Friday, February 14, 2014.

CNCE is a clinical stage biopharmaceutical company applying its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs.

(5) Based in Burlington, MA, Flexion Therapeutics (FLXN) scheduled a $65 million IPO on the Nasdaq with a market capitalization of $192 million at a price range midpoint of $13 for Wednesday, February 12, 2014.

FLXN is a specialty pharmaceutical company focused on the development and commercialization of novel, long-acting, injectable pain therapies. FLXN is In Phase 2 clinical trials.

(6) Based in Woodcliff Lake, NJ, Eagle Pharmaceuticals (EGRX) scheduled a $50 million IPO on the Nasdaq with a market capitalization of $209 million at a price range midpoint of $15 for Thursday, February 13, 2014.

EGRX is a specialty pharmaceutical company focused on developing and commercializing injectable products utilizing the FDA's 505(b)(2) regulatory pathway.

(7) Based in Salt Lake City, UT, Amedica (AMDA) scheduled a $35 million IPO on the Nasdaq with a market capitalization of $125 million at a price range midpoint of $11 for Wednesday, February 12, 2014.

AMDA is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices.

(8) Based in Portland, OR, Semler Scientific (SMLR) scheduled a $15 million IPO on the Nasdaq with a market capitalization of $62 million at a price range midpoint of $13 for Friday, February 14, 2014.

SMLR has a patented blood pressure cuff for extremities, to help diagnose cardiovascular problems.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Equities.com


Story Tools